title: Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
abstract: OBJECTIVE
  Options for the treatment of well-differentiated neuroendocrine tumors (NETs) are limited. We evaluated the efficacy of capecitabine and temozolomide combination in patients from Jordan.
  
  
  METHODS
  A retrospective review was conducted of 21 patients with metastatic well-differentiated NETs who failed somatostatin analogues and chemotherapy. Patients received capecitabine and temozolomide regimen every 28 days, and evaluation was done every 2 cycles.
  
  
  RESULTS
  Twelve patients (57%) achieved partial response, and 5 (23%) achieved stable disease. Median progression-free survival was 16.5 months (range, 14.8-18 months). Of the 7 carcinoid tumors, 2 had partial response, and 2 had stable disease. There were no grade 4 toxicities or treatment-related deaths.
  
  
  CONCLUSIONS
  Capecitabine and temozolomide regimen is an effective and well-tolerated salvage option for well-differentiated NETs.
authors.affiliation: From the Departments of *Oncology and †Nursing, King Hussein Cancer Center, Amman, Jordan.
authors.forename: Salah
authors.initials: S
authors.lastname: Abbasi
authors.forename: Amneh
authors.initials: A
authors.lastname: Kashashna
authors.forename: Hamzeh
authors.initials: H
authors.lastname: Albaba
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D002276:Carcinoid Tumor / Q000188:drug therapy / Q000453:epidemiology; D002454:Cell Differentiation; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003906:Developing Countries; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007597:Jordan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology / Q000556:secondary*; D012074:Remission Induction; D012189:Retrospective Studies; D016879:Salvage Therapy; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D003841:Deoxycytidine; D000069287:Capecitabine; D003606:Dacarbazine; D005472:Fluorouracil; D000077204:Temozolomide